JUPITER NEUROSCIENCES, INC.
For the period ended Sep 30, 2025. Filed Nov 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 14, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statement of Changes in Stockholders’ Deficit
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT)
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024
For the Three Months Ended September 30, 2025
| Common Stock · Additional Paid in · Accumulated · Total Stockholders’ Equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount · Capital · Deficit · (Deficit) | ||||||
| June 30, 2025 | 34,833,083 | $3,483 | $31,140,596 | - | $(29,803,961) | $1,340,118 |
| Stock-based compensation | - | - | 792,725 | - | 792,725 | |
| Shares issued for warrant exercises | 943,846 | 94 | (94) | - | - | |
| Shares issued in connection with warrant amendments | 143,654 | 15 | 212,593 | - | 212,608 | |
| Shares not issued for vested restricted stock units due to administrative delay – See Note 6 | (1,626,037) | (163) | 163 | - | - | |
| Net loss | - | - | - | - | (2,288,034) | (2,288,034) |
| September 30, 2025 | 34,294,546 | $3,429 | $32,145,983 | - | $(32,091,995) | $57,417 |
For the Nine Months Ended September 30, 2025
| Common Stock · Additional Paid in · Accumulated · Total Stockholders’ Equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount · Capital · Deficit · (Deficit) | ||||||
| December 31, 2024 | 33,103,860 | $3,310 | $30,190,827 | - | $(26,022,129) | $4,172,008 |
| Stock-based compensation | - | - | 1,676,667 | - | 1,676,667 | |
| Shares issued for services rendered | 103,186 | 10 | 65,990 | - | 66,000 | |
| Shares issued for warrant exercises | 943,846 | 94 | (94) | - | - | |
| Shares issued in connection with warrant amendments | 143,654 | 15 | 212,593 | - | 212,608 | |
| Net loss | - | - | - | - | (6,069,866) | (6,069,866) |
| September 30, 2025 | 34,294,546 | $3,429 | $32,145,983 | - | $(32,091,995) | $57,417 |
For the Three Months Ended September 30, 2024
| Common Stock · Additional Paid in · Receivables for Sale of Common · Accumulated · Total Stockholders’ Equity | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Stock | Deficit | (Deficit) | |
| June 30, 2024 | 30,126,413 | $3,012 | $18,620,438 | $(75,000) | $(23,903,481) | $(5,355,031) |
| Stock-based compensation | - | - | 195,056 | - | - | 195,056 |
| Net loss | - | - | - | - | (591,021) | (591,021) |
| September 30, 2024 | 30,126,413 | $3,012 | $18,815,494 | $(75,000) | $(24,494,502) | $(5,750,996) |
For the Nine Months Ended September 30, 2024
| Receivables for · Total | |||||||
|---|---|---|---|---|---|---|---|
| Common Stock · Additional Paid in · Sale of Common · Accumulated · Stockholders’ Equity | |||||||
| Shares · Amount · Capital · Stock · Deficit · (Deficit) | |||||||
| December 31, 2023 | 26,526,405 | $2,652 | $17,778,498 | $ | - | $(23,582,504) | $(5,801,354) |
| Stock-based compensation | - | - | 827,356 | - | - | 827,356 | |
| Issuance of restricted stock and stock options for accrued compensation | - | - | 60,000 | - | - | 60,000 | |
| Shares issued for vesting of restricted stock | 3,487,500 | 349 | (349) | - | - | - | |
| Sale of common stock, net of receivables of $75,000 | 112,500 | 11 | 149,989 | (75,000) | - | 75,000 | |
| Reconciling shares due to forward stock split | 8 | - | - | - | - | - | |
| Net loss | - | - | - | - | (911,998) | (911,998) | |
| September 30, 2024 | 30,126,413 | $3,012 | $18,815,494 | $(75,000) | $(24,494,502) | $(5,750,996) | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.